Clinical Trials
6 trialsNCT04417621 2026-03-12
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Novartis
Phase 2 Active not recruiting
NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
NCT02974725 2025-04-13
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Novartis
Phase 1 Terminated
NCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT01777776 2016-09-13
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Array BioPharma
Phase 1/2 Terminated